ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 299

A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis

Angelo Ravelli1,2, Giulia Bracciolini3, Sergio Davì3, Angela Pistorio4, Alessandro Consolaro4, Sara Verazza3, Bianca Lattanzi4, Giovanni Filocamo4, Sara Dalprà3, Maurizio Gattinara5, Valeria Gerloni6, Antonella Insalaco7, Fabrizio De Benedetti Sr.8, Adele Civino9, Luciana Breda10, Loredana Lepore11, Maria Cristina Maggio12, Franco Garofalo13, Silvia Magni-Manzoni14, Donato Rigante15, Antonella Buoncompagni4, Marco Gattorno4, Clara Malattia16, Stefania Viola17, Paolo Picco4, Nicolino Ruperto18 and Alberto Martini1, 1Istituto Giannina Gaslini and University of Genova, Genova, Italy, 2University of Genova, Genova, Italy, 3Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 4Istituto Giannina Gaslini, Genova, Italy, 5Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, 6Pediatric Rheumatology Unit, Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, 7Department of Pediatric Medicine,, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 8Clinica Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma, Italy, 9Ospedale Cardinale G. Panico, Tricase, Italy, 10Ospedale Policlinico, Chieti, Italy, 11Istituto Burlo Garofolo, Trieste, Italy, 12University of Palermo, Palermo, Italy, 13Ospedale degli Infermi, Biella, Italy, 14Ospedale Pediatrico Bambino Gesù, Roma, Italy, 15Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy, 16Claramalattia@Ospedale-Gaslini, Istituto Giannina Gaslini and University of Genova, Genova, Italy, 17Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, 18Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Joint procedures, juvenile idiopathic arthritis (JIA) and methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose In contrast with the numerous randomized controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular JIA. As a result, the management of children with this subtype, which is the most prevalent in Western countries, is largely empiric. Intra-articular corticosteroid (IAC) injection is the therapy of first choice for oligoarthritis in many pediatric rheumatology centers. However, although IAC injections are usually highly efficacious, relapses of synovitis are common and sometimes occur only a few months after the procedure. It is still unclear whether concomitant administration of methotrexate (MTX) may increase and prolong the effectiveness of IAC injections. The aim of the study was to compare the efficacy of IAC injection administered as monotherapy or in association with MTX in children with oligoarticular JIA in a phase II, randomized, actively controlled, multicenter trial. 

Methods Inclusion criteria were oligoarticular JIA by ILAR criteria, age < 18 years, and parent informed consent. Patients who were previously treated with synthetic or biologic DMARDs, had undergone an IAC injection < 3 months, were newly injected only in 1 knee, or had active uveitis were excluded. Patients enrolled were randomized 1:1 to receive either IAC therapy alone (Arm 1) or IAC therapy plus MTX (Arm 2). MTX was given orally at 15 mg/m2/week (maximum 20 mg/week). All patients were followed for 12 months and were assessed at 3, 6 and 12 months. The primary outcome was synovitis flare, defined as recurrence, persistence or new onset of synovitis in 1 or more injected or uninjected (i.e. previously unaffected) joints. Flare rate/probability was compared by chi-square and Kaplan-Meier methods. 

Results

A total of 207 patients (50 boys and 157 girls) were enrolled, 102 in Arm 1 and 105 in Arm 2. Fifteen patients lost to follow-up <6 months were included only in the intention-to-treat (ITT) cohort. Patients in arms 1 and 2 were comparable for demographic features and median number of injected joints (2 vs. 2). In the ITT cohort (n=207) flare of synovitis occurred in 133 patients (64.2%), 69 (67.6%) in Arm 1 and 64 (60.9%) in Arm 2 (p=0.31), whereas in the as-observed (AO) cohort (n=192) flare of synovitis occurred in 118 patients (61.4%), 64 (66%) in Arm 1 and 54 (56.8%) in Arm 2 (p=0.19). By Kaplan-Meier analysis, the probability of synovitis flare in the 2 treatment arms was comparable in both ITT and AO cohorts (log-Rank test: p=0.18 and 0.07, respectively). However, among the 118 patients who flared in the AO cohort, flare in injected joints occurred more frequently in Arm 1 than in Arm 2 (46/64, 71.9% vs. 29/54, 53.7%; p=0.04). 

Conclusion Flare of synovitis in injected joints occurred less frequently in patients who received concomitant MTX. However, the association of oral MTX did not increase the overall effectiveness of IAC therapy, owing to the high frequency of new onset of synovitis in uninjected joints. Trial registration identifying number: FARM7Y279L, AIFA, Italy


Disclosure:

A. Ravelli,
None;

G. Bracciolini,
None;

S. Davì,
None;

A. Pistorio,
None;

A. Consolaro,
None;

S. Verazza,
None;

B. Lattanzi,
None;

G. Filocamo,
None;

S. Dalprà,
None;

M. Gattinara,
None;

V. Gerloni,
None;

A. Insalaco,
None;

F. De Benedetti Sr.,
None;

A. Civino,
None;

L. Breda,
None;

L. Lepore,
None;

M. C. Maggio,
None;

F. Garofalo,
None;

S. Magni-Manzoni,
None;

D. Rigante,
None;

A. Buoncompagni,
None;

M. Gattorno,
None;

C. Malattia,
None;

S. Viola,
None;

P. Picco,
None;

N. Ruperto,
None;

A. Martini,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-controlled-trial-of-intra-articular-corticosteroids-with-or-without-methotrexate-in-oligoarticular-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology